RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.653
+0.001 (+0.077%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.652
Open0.660
Bid0.600 x 9900
Ask0.680 x 3000
Day's Range0.640 - 0.679
52 Week Range0.610 - 6.450
Volume229,181
Avg. Volume225,838
Market Cap20.215M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018
    PR Newswireyesterday

    Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018

    SAN CLEMENTE, Calif., April 18, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that over 40 surgeons were trained to implant the ReShape BalloonTM during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World Congress that was held in Seattle from April 11-14, 2018. ReShape Lifesciences was a participant in the Endoscopic Surgery Bariatric Endoscopy Hands-On Course that was held as part of SAGES.  One of the course objectives was for the participating endoscopic surgeons to learn to integrate emerging technologies for weight-loss into their practices through hands-on experience.  Over 40 surgeons chose to be educated and trained on the ReShape Balloon technology during the course.

  • ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
    PR Newswire9 days ago

    ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes

    SAN CLEMENTE, Calif., April 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences™ neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2 diabetes.  Results of a recent study, which examines this first-ever application for the treatment of type 2 diabetes, will be discussed in a poster presentation during the Minnesota Neuromodulation Symposium taking place at the Graduate Minneapolis Hotel from April 12-13, 2018.

  • ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia
    PR Newswire16 days ago

    ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia

    SAN CLEMENTE, Calif., April 3, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced approval of the Company's ReShape Balloon™ by the Kingdom of Saudi Arabia Saudi Food and Drug Authority. Congruent with this approval, the Company received an initial stocking order from Dar Al Zahrawi Medical Co LLC, KSA.

  • ReShape Lifesciences Announces Fourth Quarter and Year End 2017 Financial Results
    PR Newswire17 days ago

    ReShape Lifesciences Announces Fourth Quarter and Year End 2017 Financial Results

    SAN CLEMENTE, Calif. , April 2, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ACCESSWIRE17 days ago

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / ReShape Lifesciences, Inc. (NASDAQ: RSLS ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:30 PM Eastern ...

  • ReShape Lifesciences Announces $6 Million Registered Direct Offering
    PR Newswire17 days ago

    ReShape Lifesciences Announces $6 Million Registered Direct Offering

    SAN CLEMENTE, Calif., April 2, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into a securities purchase agreement with an institutional investor providing for the purchase and sale in a registered direct offering of shares of series D convertible preferred stock and a warrant to purchase shares of common stock for a purchase price of $6.0 million. The shares of series D convertible preferred stock will be convertible into an aggregate of 8.0 million shares of common stock at a conversion price of $0.75 per share and the warrants will have a one-year term (or, if later, eight months after the requisite stockholder approval is obtained) and be exercisable for 35 million shares of common stock at an exercise price of $0.75 per share.

  • ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018
    PR Newswirelast month

    ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018

    SAN CLEMENTE, Calif., March 20, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will be rescheduling its conference call to discuss financial results for the fourth quarter and full year 2017 to Monday, April 2, 2018 at 1:30 PM Pacific Time. ReShape Lifesciences management is in the process of reviewing the ReShape product lines and cost structure as it completes the integration of ReShape Medical and BarioSurg into the company.  The company believes it can further reduce operating expenses, after accounting for integration-related expenses, by roughly 25%, resulting in a target cash burn of approximately $1.8 million per month, which is reduced from the earlier guidance of $2.5 million per month.  Management of ReShape Lifesciences will share further details on the integration and on financial results for the fourth quarter and full year 2017 on the conference call on April 2, 2018.

  • ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting
    PR Newswirelast month

    ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting

    SAN CLEMENTE, Calif. , March 16, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for Envision Healthcare, Taylor Morrison Home, Vertex Pharmaceuticals, ReShape Lifesciences Inc., American Axle & Manufacturing, and Lattice Semiconductor — Fundamental Analysis, Key Performance Indications

    NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018
    PR Newswirelast month

    ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018

    SAN CLEMENTE, Calif. , March 8, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced ...

  • ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities
    PR Newswirelast month

    ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities

    SAN CLEMENTE, Calif., March 7, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced an exclusive federal government business channel sales agreement with Academy Medical, LLC to sell its ReShape Balloon™ and ReShape vBloc™ products to U.S. Department of Defense (DoD) medical facilities. Through this agreement, the ReShape Balloon and ReShape vBloc are both now approved products for sale into DoD medical facilities. This new agreement adds increased distribution by Academy Medical of ReShape vBloc, which has been distributed through Academy Medical to VA facilities since May 2016.  Academy Medical is a certified Service-Disabled Veteran-Owned Small Business specializing in the distribution of medical products to VA and DoD hospitals and community-based outpatient clinics.

  • ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in Journal of Clinical Gastroenterology and Hepatology
    PR Newswirelast month

    ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in Journal of Clinical Gastroenterology and Hepatology

    SAN CLEMENTE, Calif., March 5, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that results from a study examining real-world safety and efficacy of the ReShape BalloonTM were published in the February issue of The Journal of Clinical Gastroenterology and Hepatology. The publication, titled "Real-world Safety and Efficacy of Fluid-Filled Dual Intra-Gastric Balloon for Weight Loss" discusses a retrospective, physician-sponsored study of data collected on 202 adults at two academic centers and five private practices in which all patients paid for the ReShape Balloon procedure and follow-up visits out of pocket. All patients had the ReShape Balloon inserted for weight loss therapy and the Balloon was removed from each patient after six months.

  • ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium
    PR Newswire2 months ago

    ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium

    SAN CLEMENTE, Calif. , Feb. 22, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today ...

  • ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue
    PR Newswire3 months ago

    ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue

    SAN CLEMENTE, Calif., Feb. 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today preliminary revenue results for the fourth quarter and year ended December 31, 2017. Preliminary and unaudited revenue for fourth quarter 2017, which includes revenue resulting from the October 2, 2017 acquisition of ReShape Medical, is expected to be approximately $795,000, with approximately $720,000 in revenue from ReShape® Balloons and approximately $75,000 in vBloc® revenue generated during the fourth quarter of 2017. Preliminary and unaudited revenue for full year 2017, which includes fourth quarter revenue resulting from the October 2, 2017 acquisition of ReShape Medical, is expected to be approximately $1.3 million, with approximately $720,000 in revenue from ReShape Balloons and approximately $570,000 in vBloc revenue that was generated during the year ended December 31, 2017.

  • ReShape Lifesciences Announces 2017 Weight Loss Contest Winner
    PR Newswire3 months ago

    ReShape Lifesciences Announces 2017 Weight Loss Contest Winner

    The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost during the 6-month ReShape Balloon implant period, followed by continued weight loss of the remaining 20 pounds after device removal. The patient, a female, age 53, had the ReShape Balloon placed by Dr. Vivek Kumbhari, MD, Director of Endoscopy at Johns Hopkins Bayview Medical Center & Director of Bariatric Endoscopy at Johns Hopkins Weight Management Center.

  • ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
    Capital Cube4 months ago

    ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017

    Categories: Yahoo FinanceGet free summary analysis ReShape Lifesciences, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ReShape Lifesciences, Inc. – LivaNova Plc, Misonix, Inc. and Medtronic plc (LIVN-US, MSON-US and MDT-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
    PR Newswire4 months ago

    ReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai

    SAN CLEMENTE, Calif., Dec. 13, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape® Integrated Dual Balloon System from Al Zahrawi Medical, a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar.  This order, the second since Al Zawhari's initial stocking order in August 2017, is to support increased demand for the Reshape Integrated Dual Balloon System from a leading hospital customer's growing bariatric program in Dubai.

  • PR Newswire4 months ago

    ReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom Company

    SAN CLEMENTE, Calif., Dec. 4, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that their ReShape Integrated Dual Balloon technology has been granted employee coverage through a supplemental coverage policy at a multinational telecommunications corporation that provides mobile telephone, fixed telephone and broadband subscription television services. "Obesity is an epidemic with a global economic impact of over $2 trillion, and obese adults spend over 40% more on healthcare than those at a healthy weight," said Dan Gladney, President, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. The telecommunications company employs over 260,000 people worldwide, and the ReShape Dual Balloon is the only intragastric balloon listed and exclusively covered for certain of these employees as a benefit through one of their internal benefits programs that partners with many corporations for coverage of their employees and retirees.

  • ReShape Lifesciences Announces Third Quarter 2017 Financial Results
    PR Newswire5 months ago

    ReShape Lifesciences Announces Third Quarter 2017 Financial Results

    SAN CLEMENTE, Calif. , Nov. 14, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • ReShape Lifesciences Presents New Data on Obesity Technologies
    PR Newswire5 months ago

    ReShape Lifesciences Presents New Data on Obesity Technologies

    SAN CLEMENTE, Calif., Nov. 3, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented this week at the ObesityWeek 2017 conference in Washington D.C. "Obesity has become a global epidemic that involves significant health issues, comorbidities, and high associated costs to the healthcare system," said Dan Gladney, President, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences. The presentation discussed 342 patients that were implanted with the ReShape® Integrated Dual Balloon at a multicenter bariatric practice (mean age of 45, average weight of 231 lbs., average Body Mass Index (BMI) of 38, 76% female).

  • ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017
    PR Newswire6 months ago

    ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017

    SAN CLEMENTE, Calif. , Oct. 31, 2017 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced ...